pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·6h ago·1 min read
save

GOP health policy guru continues to support $1 trillion Medicaid cuts, warning of next target

Sep 22, 2026·read at STAT ↗RegulatoryNegative

Brian Blase, president of the Paragon Health Institute, has become a trusted adviser to Republican lawmakers and has publicly defended sweeping Medicaid reductions.

The One Big Beautiful Bill Act, which Blase helped shape, is projected to cut Medicaid spending by about $1 trillion over the next decade, a move intended to offset recent tax cuts. The nonpartisan Congressional Budget Office estimates the cuts could strip coverage from roughly 7 million people.

Health providers are scrambling to redesign care models as the funding landscape shifts, while critics argue the cuts will worsen health outcomes for vulnerable populations.

Blase maintains that the reductions are fiscally responsible and necessary, even as the policy debate intensifies and backlash grows among patient advocates.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Why an influential GOP health policy expert still backs the Medicaid cuts — and which policy target is next”

read at STAT ↗
495 words · retrieved 5h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1h agoSTAT+: Novo may be getting a better deal than expected with Medicare’s Bridge programSTAT
  • 2h agoSTAT+: Epic’s mortality model, and Omada’s future productsSTAT
  • 2h agoSTAT+: Pharmalittle: We’re reading about pharma seeking to protect China deals, a Roche obesity drug, and moreSTAT
  • 3h agoNew federal autism committee head has financial ties to leucovorinSTAT
  • 6h agoOpinion: The science on relieving cancer symptoms is clear. Why isn’t insurance paying?STAT